All In Biotech

Drug Trial Radar · NCT05977023

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

NMDA Receptor Modulation for the Treatment of Cognitive Impairment and Perceived Stress in Bipolar I Disorder

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 4, 2023

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
China Medical University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Science and Technology Council
First posted
Aug 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.

Conditions

  • Bipolar I Disorder

Interventions

  • NMDAEDrug

    Use of an NMDA enhancer for the treatment of bipolar depression

  • Placebo CapDrug

    Use of placebo as a comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Visual Continuous Performance TestTime frame: week 0, 8
  2. Change in Wisconsin Card Sorting TestTime frame: week 0, 8
  3. Change in Logical Memory Test of the Wechsler Memory ScaleTime frame: week 0, 8
  4. Digit SpanTime frame: week 0, 8
  5. Spatial SpanTime frame: week 0, 8
  6. Category FluencyTime frame: week 0, 8
  7. Trail Marking ATime frame: week 0, 8
  8. WAIS-III Digit Symbol-CodingTime frame: week 0, 8
  9. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0Time frame: week 0, 8
  10. Change in Perceived Stress Scale in Perceived Stress ScaleTime frame: week 0, 2, 4, 6, 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Psychiatry, China Medical University Hospital

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.